A Golden Era for Pharma in 2020
More favourable conditions for the pharmaceutical industry, including a "golden era of renewed productivity and prosperity" have been forecast in a new report from analyst firm PricewaterhouseCoopers (PwC).
More favourable conditions for the pharmaceutical industry, including a “golden era of renewed productivity and prosperity” have been forecast in a new report from analyst firm PricewaterhouseCoopers (PwC). According to the report, major scientific and technological advances, coupled with sociodemographic changes, increasing demand for medicines and trade liberalism, will help to transform the industry’s fortunes in 2020.
The report explains that there are three major challenges facing the industry at the moment: rising customer expectations, poor scientific productivity, and prevailing management culture, mental models and strategies that companies still rely on.
In addition, the report explains that there is a need to alter the concept of healthcare. Several industry trends have converged to increase the costs of healthcare and a proposed model is to focus on curing or preventing disease rather than treating it.
Several steps are described that pharmaceutical companies can take to ensure they make it through the challenges ahead and survive until 2020:
- Provide real-world data on medicines’ outcomes. Pooling data can provide vast knowledge about disease states and patient populations.
- Decide how much to invest in growth markets. The biggest markets may not be the most profitable ones. In addition, the costs of setting up local manufacturing may outweigh additional custom.
- Consider the implications of investing in new treatment types, such as vaccines and regenerative medicines. Be selective about the diseases approached.
- Invest more heavily in genetics and genomics, and revise R&D processes. Knowledge of genetics and genomics can lead to more effective personalised medicines.
- Collaborate with academia, government and nongovernment organisations, and other companies to access the best science and expertise.
- Companies need to focus on innovation that addresses the needs of patients, payers and providers.
The report, From Vision to Decision Pharma 2020, can be downloaded for free from PricewaterhouseCoopers .
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
